Feedback / Questions
ETX-636 - Ensem Therap
https://www.businesswire.com/news/home/20250701035370/en/Ensem-Therapeutics-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Trial-of-ETX-636-a-Potential-Best-In-Class-Allosteric-Pan-Mutant-Selective-PI3K-Inhibitor-and-Degrader
Jul 1, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next